About InVivoSIM anti-sclerostin (SOST) (Romosozumab Biosimilar) This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Romosozumab, making it ideal for research use. Romosozumab is a humanized IgG2κ monoclonal antibody that targets sclerostin (SOST), a secreted glycoprotein produced by osteocytes. Sclerostin negatively regulates bone formation by binding LRP4/5/6 and inhibiting Wnt/β‑catenin signaling—a key pathway for osteoblast activity. By neutralizing sclerostin, Romosozumab promotes bone formation while simultaneously suppressing bone resorption. This Romosozumab biosimilar is intended for non-therapeutic research use and can support studies on osteoanabolic mechanisms, Wnt signaling, and sclerostin function in bone biology. InVivoSIM anti-sclerostin (SOST) (Romosozumab Biosimilar) Specifications IsotypeHuman IgG2, κ Recommended Isotype Control(s)RecombiMAb human IgG2 isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 6.0T Dilution Buffer ImmunogenHuman SOST Reported ApplicationsIn vitro and ex vivo assays of sclerostin neutralization ELISA Western blot Flow cytometry FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
